Protecting the world against pertussis and other global emerging diseases
BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced many proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across all continents.
State-of-the-art manufacturing capabilities
BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements. BioNet aims to integrate quality beyond compliance in both products and processes through continuous improvement of our quality system.
Our vaccines are manufactured in accordance to Good Manufacturing Practices (GMP) PIC/S standards, and tested at each manufacturing step as per pharmacopeia requirements in our own quality control and testing facilities.
BioNet Key Facts
3
licensed
recombinant pertussis vaccines
200+
qualified and passionate individuals fueling vaccine innovation
25+
years’ experience
in vaccines
20
clinical trials
conducted
10+
mRNA
candidates
BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN
Jakarta, May 28, 2025 — BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia’s state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on the development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).
Signed during the State Visit of French President Emmanuel Macron to Indonesia, the agreement underscores a shared commitment to accelerating access to innovative vaccines across Southeast Asia. The partnership combines BioNet’s proprietary recombinant pertussis technology and global clinical development experience with Bio Farma’s large-scale manufacturing capabilities and public health reach to address critical immunization needs in ASEAN.
BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation
BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in collaboration with LTS Lohmann Therapie-Systeme AG, this recognition underscores BioNet’s contributions to mRNA vaccine technologies and their transformative potential to improve global health. Read more >
BARDA announces $8 million in awards to advance microneedle patch-based RNA vaccine development as part of the Patch Forward Prize
Today, the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), announced four winners of the Concept Stage of the Patch Forward Prize. Read more >
